[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 12, 2000

Interleukin 2 Treatment for HIV Infection

Author Affiliations

Author Affiliations: Johns Hopkins University School of Medicine, Baltimore, Md.

JAMA. 2000;284(2):236-238. doi:10.1001/jama.284.2.236

Approaches to the treatment of human immunodeficiency virus type 1 (HIV-1) infection continue to evolve rapidly, raising complex medical and scientific questions. The advent of highly active antiretroviral therapy (HAART), involving combinations of inhibitors of HIV-1 reverse transcriptase and protease, has resulted in dramatic decreases in death rates from acquired immunodeficiency syndrome (AIDS) in the United States.1 In select patient populations participating in clinical trials of various HAART regimens, clearance of detectable virus from blood is observed in 70% to 90% of patients.24 Patients who respond to HAART show a surprising degree of reconstitution of the immune system.

First Page Preview View Large
First page PDF preview
First page PDF preview